Marisa Wexler, MS,  senior science writer—

In preparation for the World Parkinson Congress taking place in Barcelona in July, the World Parkinson Coalition (WPC) is making the city more accessible and accommodating for people with Parkinson’s disease. “A significant challenge for people living with PD [Parkinson’s disease] is traveling comfortably and safely. PD is…

People with Parkinson’s disease facing anxiety, depression, apathy, and other mental health challenges when diagnosed are more likely to experience a decline in their cognitive abilities with disease progression, a study reported. “Considering the importance of cognitive dysfunction … it is critical to identify factors that could predict a…

The Parkinson’s Progression Markers Initiative (PPMI), a landmark study from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) that aims to better understand how Parkinson’s disease develops and progresses, is expanding to people in Canada. Sites in Canada that include the Montreal Neurological Institute-Hospital (The Neuro), Toronto…

To celebrate Parkinson’s Awareness Month, Bent Water Brewing Company is releasing a beer, called Common Hope, with the aim of building awareness about Parkinson’s disease and raising money to support new treatments. Marking the second year of this initiative, created in collaboration with The Michael J. Fox…

AT-04 and AT-07, experimental therapies Attralus is developing to treat Parkinson’s disease and other neurodegenerative disorders, are able to potently bind to several proteins that form toxic clumps in these conditions. That’s according to new data shared at the AD/PD 2023-International Conference on Alzheimer’s and Parkinson’s Diseases and…

Older age at the onset of disease, high blood pressure, poor cognitive and motor function, and mutations in the APOE gene are risk factors of future cognitive impairment in newly diagnosed Parkinson’s disease, a study showed. The combination of these factors was able to more accurately predict which patients…

One year of treatment with Anavex 2-73 (blarcamesine) safely led to a reduction in symptom severity for 20 people with Parkinson’s disease dementia in an extension study of the Phase 2 ANAVEX 2-73-PDD-001 trial. This finding was in sharp contrast with the worsening of symptoms observed in the months that…

Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened paralysis in mouse models of Parkinson’s disease, according to new data from Nitrase Therapeutics. Formation of toxic aggregates of alpha-synuclein is a hallmark of Parkinson’s and “has been…

PharmaTher Holdings has received guidance from the U.S. Food and Drug Administration (FDA) on the late-stage clinical development of ketamine for levodopa-induced dyskinesia, or uncontrolled movements, in people with Parkinson’s disease. “We are satisfied with the feedback we received from the Type C meeting with the FDA, which lays…

A science team at Merck (known as MSD outside North America) is the winner of an $8.5 million competition to develop an imaging technology capable of visualizing alpha-synuclein protein in the brains of people living with Parkinson’s disease, the contest’s organizer, The Michael J. Fox Foundation for Parkinson’s…